Myriad RBM, Sanofi Collaborate
News Oct 26, 2016
Myriad RBM has announced that it will work with Sanofi to perform a biomarker analysis of blood samples from the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial (NCT01147250). “We know that cardiovascular risk is higher in people with diabetes and that cardiovascular disease negatively affects treatment outcomes,” said Riccardo Perfetti, head of Global Diabetes Medical Team, Sanofi.
“Sanofi is committed to further exploring cardiovascular disease in this patient population. The biomarker work with Myriad RBM will allow us to further develop a molecular understanding of the cardiovascular risks in people with type 2 diabetes. Biomarker profiling supports our goal of developing potentially innovative new treatments for patients.”
Under the agreement, Sanofi will provide approximately 5,300 serum samples from the ELIXA trial. Myriad RBM will use its CustomMAP® platform to measure biomarkers that can predict cardiovascular and microvascular (renal and retinal) risk in people with type 2 diabetes. Financial terms of the deal were not disclosed.
“Biomarker profiling can support the accelerated development of potentially innovative, targeted treatments for people with diabetes,” said Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine at Harvard Medical School, senior physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital.
“As the chair of the ELIXA Steering Committee, I am pleased that Sanofi is supporting this work, which will provide new insights for better predicting cardiovascular risk in people with diabetes and hopefully improve the beneficial effects of therapies.” Myriad RBM’s DiscoveryMAP® platform was used with Sanofi’s ORIGIN1 trial to successfully identify biomarkers associated with cardiovascular events or death in people with pre-diabetes or early type 2 diabetes. The performance of these biomarkers was confirmed using Myriad RBM’s CustomMAP platform and samples from Sanofi’s HOPE trial.1
“In prior studies, we demonstrated the power of DiscoveryMAP to identify panels of biomarkers that have important diagnostic and prognostic applications for people at a higher risk of a cardiovascular event. This new agreement with Sanofi will expand upon that experience,” said Ralph McDade, Ph.D., president of Myriad RBM. “Our ultimate goal is to provide accurate estimates of the risk of a future cardiovascular event in patients so that drug developers and physicians can tailor care and achieve better health outcomes.”